国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

m(6)A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas

第一作者：Chai Rui-Chao,Wu Fan,Wang Qi-Xue

通讯作者：Wang Yong-Zhi,Kang Chun-Sheng

RNA modification demethylases epigenetics methyltr

基本信息

2019-02-27

已发表文章

发表杂志：Aging

发表类型: Research Paper

影响因子(IF): 5.515

PMID: 30810537 Pubmed原文链接 全文下载

主要研究背景及目的

方法

Here, we demonstrate that most of the thirteen main m6A RNA methylation regulators are differentially expressed among gliomas stratified by different clinicopathological features in 904 gliomas. We identified two subgroups of gliomas (RM1/2) by applying consensus clustering to m6A RNA methylation regulators. Compared with the RM1 subgroup, the RM2 subgroup correlates with a poorer prognosis, higher WHO grade, and lower frequency of IDH mutation. Moreover, the hallmarks of epithelial-mesenchymal transition and TNFα signaling via NF-κB are also significantly enriched in the RM2 subgroup.

结论

In conclusion, m6A RNA methylation regulators are crucial participants in the malignant progression of gliomas and are potentially useful for prognostic stratification and treatment strategy development.

主要结果

This finding indicates that m6A RNA methylation regulators are closely associated with glioma malignancy. Based on this finding, we derived a risk signature, using seven m6A RNA methylation regulators, that is not only an independent prognostic marker but can also predict the clinicopathological features of gliomas. Moreover, m6A regulators are associated with the mesenchymal subtype and TMZ sensitivity in GBM.